Nir Melamed1, Jyotsna Shah, Amuchou Soraisham, Eugene W Yoon, Shoo K Lee, Prakesh S Shah, Kellie E Murphy. 1. Department of Obstetrics and Gynaecology, Sunnybrook Health Sciences Center, the Departments of Obstetrics and Gynecology and Paediatrics, University of Toronto, and the Departments of Pediatrics and Obstetrics and Gynecology and the Maternal-Infant Research Centre (MiCare), Mount Sinai Hospital, Toronto, Ontario, and the Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
Abstract
OBJECTIVE: To assess the association between antenatal corticosteroid administration-to-birth interval and outcomes. METHODS: In this retrospective cohort study, data on singleton neonates born between 24 0/7 and 33 6/7 weeks of gestation and admitted to tertiary neonatal units in Canada during 2010-2012 were obtained from the Canadian Neonatal Network. Neonatal outcomes were compared among four groups based on the interval between antenatal corticosteroid administration and birth: no antenatal corticosteroids, partial antenatal corticosteroids (less than 24 hours before birth), antenatal corticosteroids 1-7 days before birth, and antenatal corticosteroids greater than 7 days before birth. Composite outcome was defined as any of neonatal mortality, bronchopulmonary dysplasia, grade 3-4 intraventricular hemorrhage, periventricular leukomalacia, or stage 3 or higher retinopathy. RESULTS: Of 6,870 eligible neonates, 1,378 (20%) received no antenatal corticosteroids; 1,473 (21%) received partial antenatal corticosteroids; 2,721 (40%) received antenatal corticosteroids 1-7 days before birth; and 1,298 (19%) received antenatal corticosteroids greater than 7 days before birth. The odds of the composite adverse outcome were significantly higher in all groups compared with neonates who received antenatal corticosteroids 1-7 days before birth (no antenatal corticosteroids: adjusted odds ratio [OR] 2.12, 95% confidence interval [CI] 1.69-2.65; partial antenatal corticosteroids: adjusted OR 1.48, 95% CI 1.22-1.80; and antenatal corticosteroids at greater than 7 days: adjusted OR 1.46, 95% CI 1.20-1.77). Similar findings were observed with respect to neonatal mortality (no antenatal corticosteroids: adjusted OR 2.56, 95% CI 1.83-3.59; partial antenatal corticosteroids: adjusted OR 1.59, 95% CI 1.16-2.18; and antenatal corticosteroids at greater than 7 days: adjusted OR 1.40, 95% CI 1.00-1.97). CONCLUSION: Antenatal corticosteroids had maximum benefit when given between 1 and 7 days before birth. LEVEL OF EVIDENCE: II.
OBJECTIVE: To assess the association between antenatal corticosteroid administration-to-birth interval and outcomes. METHODS: In this retrospective cohort study, data on singleton neonates born between 24 0/7 and 33 6/7 weeks of gestation and admitted to tertiary neonatal units in Canada during 2010-2012 were obtained from the Canadian Neonatal Network. Neonatal outcomes were compared among four groups based on the interval between antenatal corticosteroid administration and birth: no antenatal corticosteroids, partial antenatal corticosteroids (less than 24 hours before birth), antenatal corticosteroids 1-7 days before birth, and antenatal corticosteroids greater than 7 days before birth. Composite outcome was defined as any of neonatal mortality, bronchopulmonary dysplasia, grade 3-4 intraventricular hemorrhage, periventricular leukomalacia, or stage 3 or higher retinopathy. RESULTS: Of 6,870 eligible neonates, 1,378 (20%) received no antenatal corticosteroids; 1,473 (21%) received partial antenatal corticosteroids; 2,721 (40%) received antenatal corticosteroids 1-7 days before birth; and 1,298 (19%) received antenatal corticosteroids greater than 7 days before birth. The odds of the composite adverse outcome were significantly higher in all groups compared with neonates who received antenatal corticosteroids 1-7 days before birth (no antenatal corticosteroids: adjusted odds ratio [OR] 2.12, 95% confidence interval [CI] 1.69-2.65; partial antenatal corticosteroids: adjusted OR 1.48, 95% CI 1.22-1.80; and antenatal corticosteroids at greater than 7 days: adjusted OR 1.46, 95% CI 1.20-1.77). Similar findings were observed with respect to neonatal mortality (no antenatal corticosteroids: adjusted OR 2.56, 95% CI 1.83-3.59; partial antenatal corticosteroids: adjusted OR 1.59, 95% CI 1.16-2.18; and antenatal corticosteroids at greater than 7 days: adjusted OR 1.40, 95% CI 1.00-1.97). CONCLUSION: Antenatal corticosteroids had maximum benefit when given between 1 and 7 days before birth. LEVEL OF EVIDENCE: II.
Authors: Mikael Norman; Aurelie Piedvache; Klaus Børch; Lene Drasbek Huusom; Anna-Karin Edstedt Bonamy; Elizabeth A Howell; Pierre-Henri Jarreau; Rolf F Maier; Ole Pryds; Liis Toome; Heili Varendi; Tom Weber; Emilija Wilson; Arno Van Heijst; Marina Cuttini; Jan Mazela; Henrique Barros; Patrick Van Reempts; Elizabeth S Draper; Jennifer Zeitlin Journal: JAMA Pediatr Date: 2017-07-01 Impact factor: 16.193
Authors: Colm P Travers; Waldemar A Carlo; Scott A McDonald; Abhik Das; Edward F Bell; Namasivayam Ambalavanan; Alan H Jobe; Ronald N Goldberg; Carl T D'Angio; Barbara J Stoll; Seetha Shankaran; Abbot R Laptook; Barbara Schmidt; Michele C Walsh; Pablo J Sánchez; M Bethany Ball; Ellen C Hale; Nancy S Newman; Rosemary D Higgins Journal: Am J Obstet Gynecol Date: 2017-11-11 Impact factor: 8.661
Authors: Montse Palacio; Elisenda Bonet-Carne; Teresa Cobo; Alvaro Perez-Moreno; Joan Sabrià; Jute Richter; Marian Kacerovsky; Bo Jacobsson; Raúl A García-Posada; Fernando Bugatto; Ramon Santisteve; Àngels Vives; Mauro Parra-Cordero; Edgar Hernandez-Andrade; José Luis Bartha; Pilar Carretero-Lucena; Kai Lit Tan; Rogelio Cruz-Martínez; Minke Burke; Suseela Vavilala; Igor Iruretagoyena; Juan Luis Delgado; Mauro Schenone; Josep Vilanova; Francesc Botet; George S H Yeo; Jon Hyett; Jan Deprest; Roberto Romero; Eduard Gratacos Journal: Am J Obstet Gynecol Date: 2017-03-23 Impact factor: 8.661
Authors: Prakesh S Shah; Sarah D McDonald; Jon Barrett; Anne Synnes; Kate Robson; Jonathan Foster; Jean-Charles Pasquier; K S Joseph; Bruno Piedboeuf; Thierry Lacaze-Masmonteil; Karel O'Brien; Sandesh Shivananda; Nils Chaillet; Petros Pechlivanoglou Journal: CMAJ Open Date: 2018-01-18
Authors: Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod Journal: Int J Gynaecol Obstet Date: 2021-03 Impact factor: 3.561
Authors: Jessica Smith; Kellie E Murphy; Sarah D McDonald; Elizabeth Asztalos; Amir Aviram; Stefania Ronzoni; Elad Mei-Dan; Arthur Zaltz; Jon Barrett; Nir Melamed Journal: Arch Gynecol Obstet Date: 2022-01-18 Impact factor: 2.493
Authors: Nir Melamed; Elizabeth Asztalos; Kellie Murphy; Arthur Zaltz; Donald Redelmeier; Baiju R Shah; Jon Barrett Journal: BMJ Open Date: 2019-09-30 Impact factor: 2.692